VGI Announces the Launch of DISMISS� Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System

VGI Announces the Launch of DISMISS® Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System

VGI introduces a revolutionary surgical instrument system that is smaller in diameter than a pencil. The DISMISS® instrument system is designed specifically for the implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will be unveiled at the Congress of Neurological Surgeons meeting in Phoenix, Arizona starting on March 12, 2009.

Winston-Salem, NC (PRWEB) March 3, 2009 -- VG Innovations, Inc. (www.vginnovations.com) (VGI), announces the launch of a new surgical instrumentation system, named DISMISS®.

"DISMISS® stands for Directional Instrument System for Minimally Invasive Spine Surgery," stated VGI's President and CEO, Dan Grayson. "We have received very positive feedback from our surgeon users, regarding the biomechanical advantages of the VerteLoc™ Minimally Invasive Spine Stabilization system, so the next logical step was to further refine the system's current instrumentation. We have now taken minimally invasive spinal facet fusion to a whole new level with the DISMISS® instruments."

"The DISMISS® instruments, used specifically for the implantation of the VerteLoc™ implants, are smaller in diameter than a pencil," noted Executive Vice President and Chief Technical Officer Dr. Tov Vestgaarden. "In addition, we have not only reduced the size, but also the number of instruments required for surgical implantation. This is just the beginning of a whole new era in surgical instrumentation from VGI."

"New sets of the DISMISS® instruments will be distributed during the second and third quarters of 2009 to select VGI distributors throughout the United States," Grayson added. "These new instruments will allow our distributors to introduce the VerteLoc™ system to a more diverse surgeon base."

The VerteLoc™ Minimally Invasive Spine Stabilization System (www.verteloc.com) is designed to allow earlier intervention in the continuum of spinal care. The procedure should prolong or prevent more invasive spine procedures in indicated patients, which would provide significant benefits to the quality of life versus traditional methods of spinal fusion.

Company Profile

VG Innovations, Inc, is a privately held company and was formed in late 2007. The company is in the business of developing and commercializing proprietary, implantable devices with a specific focus on minimally invasive surgical products that could provide better surgical solutions over present technology. The products are designed to treat specific spinal disease indications that affect millions of people. More information on the company and its products can be found at: www.verteloc.com.

###

Contact Information Dan Grayson

VG Innovations, Inc

http://www.verteloc.com

336-760-2012

The Health Alliance's Dennis Robb Announced Contracting Professional of the Year by The Journal of Healthcare Contracting

The Health Alliance's Dennis Robb Announced Contracting Professional of the Year by The Journal of Healthcare Contracting

Pioneer in healthcare supply chain honored for accomplishments

Dallas (Vocus) March 3, 2009 -- Dennis Robb, senior vice president, supply chain management (www.broadlane.com), The Health Alliance of Greater Cincinnati, was recently announced 2008 Contracting Professional of the Year by The Journal of Healthcare Contracting.

Described as a pioneer in healthcare for more than three decades, Robb was selected to receive this honor based on his accomplishments in supply chain management and history of clinical and executive leadership.

As the senior vice president of supply chain management (www.broadlane.com) for The Health Alliance of Greater Cincinnati, Robb is continually seeking avenues for improvement for the 929-bed health system and manages its $369 million supply and capital spend. Robb is also responsible for initiation of value analysis committees and leadership of multidisciplinary teams of doctors, nurses, pharmacy, information technology and bioengineering professional for the management of capital procedures, contracting and contract compliance, system-wide standardization, price verification documentation of audited savings, vendor negotiations, environmental responsibility and economic inclusion.

"We congratulate Dennis on his latest achievement," said David Ricker, president and chief executive officer, Broadlane. "He is a valuable member on our Executive Steering Committee, helping drive all contracting decisions and awards. Dennis has also emerged as a leader in Supplier Diversity, working with the Broadlane Supplier Diversity Contracting team to implement the methods by which to execute and track results of The Health Alliance's supplier diversity initiative."

One of Robb's most notable achievements is the 2008 Corris Boyd Leadership and Diversity Award from the Federation of American Hospitals. This award was presented for Robb's efforts to create an environment of cooperation and commitment within The Health Alliance, which helped the health system reach a $23 million diverse supplier spending goal in its first year.

"I work daily with Dennis on supply chain initiatives," said Ruby Kern, vice president, enterprise accounts, Broadlane. "In my 35 years of supply chain experience, I've never come across anyone as passionate as Dennis is about meeting supply chain, environmental and supplier diversity goals."

In 10 months, The Health Alliance reached and exceeded the $23 million target with certified diverse suppliers and was recognized with awards from the Greater Cincinnati and Northern Kentucky African American Chamber of Commerce and the Cincinnati USA Regional Chamber. The number of diverse suppliers grew 360 percent over a year. Over the past three years, the organization has maintained its commitment, spending a total of $90 million with diverse suppliers.

"We are very proud of Dennis' newest honor as Contracting Professional of the Year," said Ken Hanover, chief executive officer, the Health Alliance. "He has done an extraordinary job managing our supply chain. Dennis' optimism, professionalism and commitment to excellence are outstanding attributes, and this recognition is something in which we can all take pride."

About The Journal of Healthcare Contracting

The Journal of Healthcare Contracting is the only publication that is solely devoted to the contracting arena of healthcare. It focuses on the interactions of the four primary stakeholders in healthcare contracting: health systems and their facilities, manufacturers and suppliers, distributors and group purchasing organizations. The participants in the contracting arena will grow to rely on The Journal of Healthcare Contracting for industry understanding, insight into the minds of thought leaders and collaboration opportunities amongst contracting constituents.

About The Health Alliance

The Health Alliance of Greater Cincinnati, which includes the University, Jewish and Fort Hamilton hospitals, Drake Center, West Chester Medical Center and the physicians of Alliance Primary Care, continues to be Cincinnati's largest healthcare provider and recently expanded its physician practice by acquiring Greater Cincinnati Associated Physicians. The Health Alliance, which employs 7,800 people, has been recognized for its progressive supplier diversity and disability services programs. For more information on the Health Alliance, visit

www.health-alliance.com.

About Broadlane

Broadlane is the leading cost management company for healthcare providers. Broadlane's scalable business solutions optimize operational performance and achieve significant cost savings, thereby improving the overall financial performance of its clients. Its core services include supply chain management and clinical workforce management services.

Broadlane's comprehensive supply chain services include:

• Unparalleled national and custom contracting for supplies, pharmaceuticals, equipment and purchased services

• Innovative Procurement Services and purchase transaction management

• Clinical Services for managing clinical preference items and operating room and cath lab spending

• Comprehensive Materials Management Services - including outsourcing

• Informatics - benchmarking, advanced analytics and reporting

• Supply chain technology and e-commerce

Broadlane Workforce Management™ addresses nurses and allied healthcare practitioners and includes:

• External shift and agency management services

• Internal shift management, including electronic shift auctions

• Regional nurse float pool management and internal agency management

• E-commerce workforce exchange linking healthcare providers, clinical staff and agencies, enabling efficient shift management and fulfillment and reconciliation

Broadlane's clients include leading providers such as Advocate Health Care, Ascension Health, Beaumont Hospitals, CHRISTUS Health, Continuum Health Partners, Kaiser Permanente, Kindred Healthcare, MedCath Corporation, New Hanover Regional Medical Center, Sisters of Charity of Leavenworth Health System, Tenet Healthcare, The Health Alliance of Greater Cincinnati, US Oncology and UMass Memorial Health Care.

The company is headquartered in Dallas with offices in Cincinnati, Detroit, Houston, New York City and Oakland. For more information, visit www.broadlane.com.

###

Contact Information Jim Webb

http://www.broadlane.com

972-813-7782

Sunetics' New Laser Paddle Brush for Hair Enhancement Provides Largest Coverage Area of All Hand-Held Devices

Sunetics' New Laser Paddle Brush for Hair Enhancement Provides Largest Coverage Area of All Hand-Held Devices

New hair enhancement laser device offers best coverage available.

Las Vegas, NV (PRWEB) March 3, 2009 -- Sunetics International announces the official launch of the new Laser Paddle Brush, an advanced at-home hair care device for men and women with weak or thinning hair that delivers a greater degree of low level laser energy to the scalp than any other hand-held unit on the market.

"Sunetics' Laser Paddle Brush is an important advancement for consumers as it provides the maximum level of scalp coverage at a more optimal low level laser energy wavelength than any other 'brush' or 'comb' currently available," said Dr. Charles Maricle, Chief Technological Officer of Sunetics International. "Low level laser therapy has been demonstrated to effectively improve the appearance of hair, making it look fuller, thicker, shinier and healthier."

With the new Laser Paddle Brush, Sunetics has enhanced the size of the laser area by creating three rows of laser diodes utilizing 12 true laser diodes. Sunetics also uses its patented technology to expand the laser beam pattern, thus creating a superior coverage area of laser energy. The Laser Paddle Brush was developed to deliver the largest coverage area of all hand-held devices so that consumers can experience in the privacy of their own homes the maximum amount of laser energy at the optimal wavelength level. The average usage time is just 10 minutes per day, three times per week.

"Customers who use the Sunetics' Laser Paddle Brush for at-home laser hair therapy care will also be able to use it on the road when they travel since it is so portable as well as rechargeable," says John Carullo, Director of Marketing for Sunetics.

Key Facts for Consumers About the Sunetics' Laser Paddle Brush:

•    Maximum Laser Energy - Designed with 12 true laser diodes, the most of any other hand-held unit on the market. Each laser diode used for hair rejuvenation has a wavelength of 650 nm.

•    Superior Scalp Coverage - Uses multiple, wide-pattern, true laser diodes to provide maximum coverage of the scalp for men and women. The laser diodes are positioned on the brush to produce an expanded elliptical laser light pattern that provides maximum coverage of the scalp.

•    Portable - Unlike other hand-held laser devices that are plugged in, the Laser Paddle Brush is cordless and uses a rechargeable battery to make it portable and easier to use with maximum energy.

•    Unique Bristle Design - A true laser "brush," the device has over 75 soft, gentle scalp-massaging bristles. The unique soft bristles are designed to not break or damage fine or weakened hair.

•    Certified, Patented and Approved - The Laser Paddle Brush is a U.S. patented device (#7,258,695) that is CE-certified and complies with all FDA manufacturing standards and safety regulations for personal use as well as 11 FDA performance standards for laser products.

Evidence for Low Level Laser Hair Therapy:

In January of 2007, the U.S. Food and Drug Administration (FDA) officially cleared the first hand-held laser device (www.fda.gov/cdrh/pdf6/K060305.pdf) to treat hair loss and to re-grow hair.

Previous cosmetic clinical studies performed by Sunetics have shown that, as a result of its laser hair therapy program, 86-percent of participants reported the appearance of healthier hair, 78-percent reported the appearance of thicker hair, 76-percent reported the appearance of fuller hair and 85-percent of the participants reported overall satisfaction with the Sunetics Laser Hair Therapy program.

About Sunetics International

Sunetics International is a leading U.S. manufacturer of low level laser devices that are regularly used by doctors for the care of weak or thinning hair. Sunetics also offers devices for acne, wrinkles and skin rejuvenation. Established in 2003, Sunetics is a registered cosmetic manufacturer with the FDA and provides both hand-held laser devices and in-office clinical laser units. For more information about low level laser devices or products from Sunetics, visit www.sunetics.com or call 1-888-266-2232.

###

Contact Information John Carullo

Sunetics International

http://www.sunetics.com

888-266-2232

CIRM Completes Briefing Visit to Stemedica Cell Technologies

CIRM Completes Briefing Visit to Stemedica Cell Technologies

Leadership of the California Institute for Regenerative Medicine ("CIRM") completed a two part visit to Stemedica Cell Technologies, Inc. ("Stemedica") to tour its manufacturing facility, R&D lab and corporate headquarters.

San Diego, Calif. (PRWEB) March 2, 2009 -- Leadership of the California Institute for Regenerative Medicine ("CIRM") completed a two part visit to Stemedica Cell Technologies, Inc. ("Stemedica") to tour its manufacturing facility, R&D lab and corporate headquarters.

"I was glad to have the opportunity to visit Stemedica and get to know more about its leadership, plans for the future and to see first hand the assets and potential they represent to the stem cell movement in California", said Dr. Alan Trounson, President of CIRM. "We want to have strong working relationships with all sectors of California's stem cell industry, including for-profit companies like Stemedica."

Prior to Dr. Trounson's visit, Dr. Marie Csete, CIRM's Chief Scientific Officer had the opportunity to visit Stemedica's manufacturing facility and R&D laboratory. "We're delighted to see Stemedica make the effort to secure a clinical grade manufacturing license from the State of California. We believe this capability will aid numerous organizations in California and around the world in their efforts to manufacture stem cell products for clinical application", said Dr. Csete.

"We were pleased to have Dr. Trounson and Dr. Marie Csete visit our facilities and receive a briefing from our leadership", said Dr. Maynard Howe, Stemedica's Vice Chairman & CEO. "We continue to play a pivotal role in the evolution of the stem cell industry in California and believe a supportive working relationship with CIRM is an essential part of this process.

Stuart Lipton, M.D., Ph.D., Scientific Director and Senior Vice President of the Del E. Webb Center for Neuroscience, Aging and Stem Cell Research at the Burnham Institute for Medical Research, San Diego, CA, joined Dr. Trounson during his visit to Stemedica's manufacturing facility. "I was impressed with the progress that Stemedica has made on the licensing process for clinical grade allogeneic stem cell manufacturing and am excited about expanding our research relationship with the Stemedica team. Having a manufacturing resource like this in California will be a great asset to our entire research community. I anticipate that many CIRM-funded stem cell research institutions will take advantage of Stemedica's manufacturing facility that will soon become FDB (Food & Drug Board) cGMP licensed."

Dr. Nikolai Tankovich, Stemedica's President and Chief Medical Officer organized the visits for Dr. Trounson, Dr. Csete and Dr. Lipton. "We're delighted that these outstanding leaders within California's stem cell movement took the time to find out more about Stemedica and our plans to lead this industry from a manufacturing standpoint. We will continue to seek the wise counsel of CIRM in an effort to align our efforts with theirs. In addition, we are expanding our collaborative research efforts with the Burnham Institute for Medical Research and several other California stem cell research institutions", said Dr. Tankovich.

About Stemedica Technologies, Inc.:

Stemedica Cell Technologies Inc. (http://www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

About CIRM:

The California Institute for Regenerative Medicine (CIRM) was established in 2005 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. To date, the CIRM governing board has approved 229 research and facility grants totaling more than $614 million, making CIRM the largest source of funding for human stem cell research in the world. For more information, please visit http://www.cirm.ca.gov (http://www.cirm.ca.gov/).

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com.

# # #

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

Medisoft Clinical EHR Software to Be Funded By New Economic Stimulus Plan

Medisoft Clinical EHR Software to Be Funded By New Economic Stimulus Plan

The economic stimulus plan signed by President Obama includes funding for the long awaited EMR software (also called EHR Software) (electronic medical records software, or electronic health record) for doctor's offices and can result in better patient care and treatment.

(PRWEB) February 28, 2009 -- Doctors wondered when the time would come that EMR software (http://www.medicalcharting.com) would bring their offices into the future. They suspected the government would pay for it and many have not purchased the software due to this. Today they found out that indeed the government will begin footing the bill for this state of the art Medisoft Clinical EHR software (http://www.medicalcharting.com/medisoft-clinical-medisoft-emr-software.htm).

Congress passed the stimulus package which is one of the largest ever. Over $20 billion is included in the form of grants and loans as well as other incentives to spur health care into the future by paying for the latest technology. This will be a large boon to the health care industry by providing doctor's offices and clinics with the software that will allow one click access to patient information.

MedicalCharting.com is an affiliate of Selent & Associates, Inc. Founded in 1989, this Port Charlotte, Florida company started as a general business services company. However, due to the vast background in health care related services, the company changed their focus to serve medical and physician offices and health care. Members of the Charlotte County, Florida Chamber of Commerce since 1988, this is a company that has committed to making the area of medical records a simpler process for health care providers.

MedicalCharting.com is a leading provider of integrated electronic health records software is thrilled that the health care industry will finally have access to the tools it needs to manage patient's electronic medical records. By providing funding for this crucial system, the health care industry is taking one giant step forward when it comes to the safety and security of the patients who depend on it.

While doctors have waited for this technology to be implemented for years the transition will be much quicker now that the government will be funding up to $64,000 maximum per provider.

The number of Medisoft users that will be affected by this stimulus program is around 80,000 and growing. The new software offered by MedicalCharting.com, called Medisoft Clinical EMR Software (http://www.medicalcharting.com/medisoft-clinical-medisoft-emr-software.htm), is designed for 1 -5 doctor practices. With the start of government funding, doctors are being encouraged to call and discuss the setup of this program for their practice and to help determine how much they can get reimbursed. With all the benefits of EHR software such as appointment scheduling, medical billing, prescriptions, lab results and more the safety of the patient is assured using this software more than ever before. Some of the primary benefits of adoption of Electronic Medical Records or EMR Software will be more accurate prescriptions, quicker diagnosis and treatment of patients, and saving of lives.

Harry Selent, President of www.MedicalCharting.com says "This EHR software (http://www.medicalcharting.com/index.htm) (Medisoft Clinical) will allow the doctors ultimate access to the patient's medical history and avoid the duplication of tests, medications and treatments. The patient's medications, vital information, documents and all treatments received would be in one place for ease of access by the doctor treating them, and no more problems of reading physician notes and prescriptions."

Excitement is high as this much awaited program is beginning to become more of a reality. MedicalCharting.com invites doctors to contact them to discuss the prospects of this groundbreaking new era in medicine. To find out more about how to make the transition in your practice contact http://medicalcharting.com or call them at 888-691-8058 or 941-743-6666.

###

Contact Information Harry Selent

www.medicalcharting.com

http://www.medicalcharting.com

9417436666

Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article

Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article

Stemedica provides its observations and comments to the media regarding the PLoS Medicine article published online February 17, 2009. The PLoS Medicine article describes a patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated transplants of "fetal neural stem cells" in Russia starting in 2001.

San Diego, California (PRWEB) February 27, 2009 -- Stemedica Cell Technologies (http://www.stemedica.com), Inc. ("Stemedica") provided its observations and comments to the media regarding the PLoS Medicine article published online February 17, 2009. The PLoS Medicine article describes a patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated transplants of "fetal neural stem cells" in Russia starting in 2001.

"All of us at Stemedica would like to extend our condolences to the young patient involved in this situation and our hope is for a speedy and positive outcome to this unfortunate experience. Never before have we or any of our Principal Investigators ever encountered such an occurrence either in our own research or in any of the published research", said Dr. David Howe, Stemedica's Vice President and Medical Director.

"We want to use this unfortunate incident to warn those seeking stem cell therapy abroad," warns Dr. Nikolai Tankovich, President & Chief Medical Officer of Stemedica, "to make certain that the manufacturer of the stem cells used in transplantation comply with the rigid standards that have been established by the FDA and other Internationally-recognized regulatory agencies. The future of this industry and the safety of all future patients depend on such adherence." FDA Compliance and Surveillance Standards can be referenced by visiting www.fda.gov/cber/compliance.htm (http://www.fda.gov/cber/compliance.htm).

The report in PLoS, Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient (http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000029), describes the development of multifocal glioneuronal neoplasms along the spinal nerves and brain stem in a 13-year-old patient who underwent repeated transplantation procedures in an attempt to treat ataxia-telangiectasia (A-T). A-T is a progressive neurodegenerative disorder known to have an increased risk of developing cancer.

Malignancy and neoplasia are common in A-T secondary to deficient cellular and humoral immunity. This immune deficiency is a contra-indication to stem cell transplant therapy. In addition, the mutations associated with A-T in the A-T mutation gene lead to mutations in nuclear protein, which normally repairs DNA. This loss of DNA repair combined with immune deficiency in A-T increases risk of neoplasia with and without cellular transplant therapy in A-T.

"Due to age, children and adolescents have significantly increased quantities of growth factors. Adding stem cells, known for their growth factor production capabilities, to a child with this presenting condition may have been a contributing factor. As in the administration of pharmaceuticals, many of which are not recommended for use in children and adolescents in the same way as in treating adults, great care must be taken in using stem cell therapy with this population of patients", said Dr. Michael Bayer, Stemedica's Director of Medical Services.

Based on the facts and references cited within the PLoS Medicine article, researchers have discovered that some of the cells were female and had two copies of the gene that causes A-T. Karyotype testing was reported in this case which confirms inadequate testing of the stem cells prior to transplantation. "The stem cell preparation protocol provided to the parents by the treatment team was reviewed and found to be inadequate by our standards", said Dr. Howe. "No cell characteristics, cell markers or bio-safety data was present. Mechanical desegregation in the 8-12 week age fetus is not recommended. Enzymatic separation is preferred, a process that also removes any dead cells that may be present. There is also a significant lack of detail on the number of cell passages as well as the dispersion of the neurospheres", Dr. Howe went on to say.

Dr. Alex Kharazi, Stemedica's Vice President for Manufacturing & Research observed, "Limited cell culturing in only 12-16 days as described in their protocol is like using a crude primary culture of cells. There are numerous risks associated with using crude cell preparations that have not been subjected to rigid manufacturing and testing protocols such as purity, identity and potency. In addition, the antibiotics used to manufacture the stem cells, are potentially neurotoxic." Dr. Kharazi went on to say, "Overall the description provided for the manufacturing protocol was vague and a poor example of what a well thought out manufacturing and safety-driven process should be. For example, there was no data provided relating to tumorgenicity, toxicity, or bio-distribution testing of the manufactured cells in nude mice which is a mandatory requirement as a first and critical step to assessing cell safety."

"Stemedica is committed to a manufacturing process that puts safety first at all times. Our stem cell product lines go through extensive testing during several stages of the manufacturing process and are also subjected to in-depth pre-clinical studies before filing with the FDA and other regulatory agencies for clinical trials", continued Dr. Kharazi. "Nothing is more important than the welfare of the patient and there is no explanation that can justify any deviance from compliance to FDA guidelines for the manufacturing and testing of stem cells prior to administration. These are the guidelines we follow and any patient considering stem cell therapy, at any location worldwide, should confirm that the manufacturer is in full compliance before they decide to undergo stem cell transplantation." warns Dr. Kharazi.

About Stemedica Technologies, Inc.

Stemedica Cell Technologies Inc. (http://www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Stemdedica complies with the standards and guidelines established by the FDA and the FDB (Food and Drug Board) in the manufacturing and testing of its stem cells. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative diseases, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com.

###

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

Pharmacists Encourage Patients To Seek Their Guidance When Choosing OTC Medications

Pharmacists Encourage Patients To Seek Their Guidance When Choosing OTC Medications

Eighty-three percent of Patients Select OTC Products Recommended by Their Pharmacist

Washington, D.C. (Vocus) February 25, 2009 -- According to the most recent Pharmacy Today Over-the-Counter Product Survey conducted by the American Pharmacists Association (http://www.pharmacist.com/) (APhA), pharmacists believe that 83 percent of consumers purchase over-the-counter products that were recommended by their pharmacist. With more than 100,000 nonprescription medications on the market and more than 1,000 active ingredients, it's critical that patients consult their pharmacist to maximize the benefits from medications and minimize the potential for harmful drug interaction and/or side effects.

The survey, completed by nearly 1,000 APhA member and non-member pharmacists, also reveals that on average pharmacists counsel 31 patients per week about over the counter medications. Patients who seek their pharmacist's advice include patients suffering from an acute or chronic condition (92 percent), patients that are worried about using an OTC product with other prescription medications (84 percent), and patients worried about taking OTC products with a specific disease/condition (74 percent).

"Pharmacists are the only health professionals specifically trained in nonprescription medications," said John A. Gans, APhA's Chief Executive Officer. "Patients can take an active role in self care by reading medication labels, knowing the active ingredients in their medications, and asking their pharmacist questions."

One of APhA's goal in conducting the annual Pharmacy Today Over-the-Counter Product Survey is to educate consumers that pharmacists have the knowledge and training to help them select right OTC medications. As part of the survey, pharmacists are asked to tabulate the OTC products they recommend per week in 77 different product categories. The results of the survey are published as a supplement to the February issue of Pharmacy Today (http://www.pharmacytoday.org/index.htm). Click here to view the entire Pharmacy Today Over-the-Counter (http://www.pharmacytoday.org/index.htm) Supplement.

As the medication experts, pharmacists are trained in both prescription and over-the-counter medications and can provide patients with important information about how medications may interact with certain foods, other medicines or dietary supplements. Pharmacists are the most accessible health care providers and APhA encourages patients to actively seek their advice about the proper use of medications.

About the American Pharmacists Association (APhA)

The American Pharmacists Association (http://www.pharmacist.com/), founded in 1852 as the American Pharmaceutical Association, represents more than 62,000 practicing pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians, and others interested in advancing the profession. APhA, dedicated to helping all pharmacists improve medication use and advance patient care, is the first-established and largest association of pharmacists in the United States. APhA members provide care in all practice settings, including community pharmacies, health systems, long-term care facilities, managed care organizations, hospice settings, and the uniformed services.

###

Contact Information Erin Wendel

American Pharmacists Association

http://www.pharmacist.com/

202.429.7558

American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer

American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer

American TeleCare, the Leader in Technology-Enabled Telehealth Solutions, Adds Accomplished Financial Executive to its Senior Management Team

Minneapolis (PRWEB) February 25, 2009 -- American TeleCare, Inc. (ATI) announced that Michael A. Brodeur has joined the company as its chief financial officer. ATI is the leader in the development and application of video-based telehealth solutions to advance patient care.

"Mike is a seasoned executive with more than 25 years of high-level financial management experience in the health care, medical device, biotechnology and clinical laboratory industries," said Randy Moore, M.D., M.B.A., chairman and chief executive officer, American TeleCare (ATI). "He brings ATI exceptional expertise in corporate finance, business development and the capital markets."

"With solutions that combine telecommunications technology with unmatched clinical functionality, ATI is at the forefront of the telehealth industry," said Brodeur. "Managing the costs of caring for patients with complex, chronic conditions is a fundamental challenge in health system reform. ATI is positioned to lead the way to establish new models of telehealth-supported care that connect high-risk patients to essential clinical expertise."

Immediately before joining ATI, Brodeur was the chief financial officer of Medical CV, Inc. (NASDAQ:MDCV), developer and manufacturer of laser-based surgical devices. He has also served as CFO of McKesson Medical Management (a $500 million pharmacy outsource provider to hospitals) and Meris Laboratories, Inc. (a $50 million clinical laboratory testing company). He previously held other senior financial leadership positions with EPS Solutions Corporation and WellPoint Health Networks, Inc., now WellPoint, Inc. (NYSE:WLP), which today is the nation's largest health insurer by member numbers. Brodeur was a managing partner at Prairieview CFO Partners, LLP, a CFO services firm for public and pre-IPO emerging and middle-market businesses. And as senior partner at Tatum CFO Partners, LLP, another national CFO services firm, he served as CFO of Molecular Diagnostics, Inc., now CytoCore, Inc. (OTCBB:CYTO) and Aastrom Biosciences, Inc. (NASDAQ:ASTM).

Brodeur is a certified public accountant who began his career at Ernst & Young. He earned a bachelor's of science degree in business administration and accountancy at California State University, Long Beach, Calif.

About American TeleCare, Inc. (ATI)

Founded in 1993, American TeleCare (ATI) is the pioneer of intelligent monitoring and video-based telehealth technology. With proven experience in clinical process re-engineering, ATI works with leading healthcare organizations to put their patients at the center of care teams and supports them with best-in-class solutions. ATI systems connect continuous healing relationships and deliver essential information for clinical and self care. Ongoing monitoring and constant care of patients at home keeps them connected to clinical expertise and may help prevent acute events. The results: 100-200 percent increases in provider productivity and 65-95 percent reductions in emergency room and inpatient costs - achieved as care teams help physicians watch over, improve and maintain their patients' health. For more information, visit www.americantelecare.com. Then call 800-323-6667.

NOTE: American TeleCare will exhibit at the American Telemedicine Association (ATA) Annual International Meeting & Exposition, which will be held on April 26-28, 2009 at the Rio All-Suites Hotel and Casino, Las Vegas, Nev. American TeleCare will be at booth #300.

###

Contact Information DAVID AQUILINA

American TeleCare, Inc. (ATI)

http://www.americantelecare.com

612.922.5551

Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials

Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials

Stemedica Cell Technologies, Inc. announced today that it has filed with the Food and Drug Branch of the State of California's Department of Public Health for certification as a licensed manufacturer of adult stem cells for U.S.-based Phase I and Phase II Clinical Trials.

San Diego, CA (PRWEB) February 25, 2009 -- Stemedica Cell Technologies (http://www.stemedica.com), Inc. ("Stemedica") announced today that it has filed with the Food and Drug Branch of the State of California's Department of Public Health for certification as a licensed manufacturer of adult stem cells for U.S.-based Phase I and Phase II Clinical Trials. Readiness for manufacture includes obtaining a California Drug Manufacturing License for the Stemedica facility in San Diego, California.

"Completion of this certification will allow us to manufacture stem cells under contract for clinical trials for Stemedica as well as for other companies and research centers in California and across the United States. This marks a significant milestone along the journey toward the future availability of stem cell treatment for patients who so urgently need it," said Dr. Maynard Howe, Vice Chairman and CEO at Stemedica.

To prepare for inspection, Stemedica fully reconstructed its facility according to FDA requirements, which had previously focused on research and development. Stemedica's manufacturing facility now includes a fully compliant manufacturing wing with entry-level gowning rooms, two ISO class 8 sterile gowning suites, an ISO Class 7 Manufacturing Clean Room, an ISO Class 7 Processing Clean Room, a Good Manufacturing Process compliant materials warehouse and a controlled-access Quality Control testing laboratory.

"As soon as Stemedica secures its license from the State of California's Department of Public Health, we plan on filing for one or more IND's (Investigative New Drug) for specific indications with the FDA using our proprietary technology. The final major step by the Food and Drug Branch within the Department of Public Health is an in-depth, in-person inspection by their personnel. We're particularly proud of the fact that we are ready for, and capable of, seeking licensing in California, which has exceptionally stringent standards," said Dr. Alex Kharazi, Vice President, Research & Manufacturing at Stemedica.

"Becoming a Licensed Manufacturer of clinical grade adult stem cells is a significant scientific and medical step forward for the Company," said Dr. Nikolai Tankovich, Stemedica's President and Chief Medical Officer. "Securing this status will allow us to become a primary CMO (Contract Manufacturing Organization) for other for-profit companies and the many research organizations interested in advancing stem cell research through clinical application. Additionally, achieving this regulatory status within the manufacturing world will provide Stemedica with the foundation to advance its own Phase I and Phase II Clinical Studies once approved by the FDA."

About Stemedica Technologies, Inc.

Stemedica Cell Technologies Inc. (www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica: Dave McGuigan -- dmcguigan (at) stemedica.com.

###

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

Alternative Surface Disinfection Explored in Latest Issue of American Journal of Infection Control (AJIC)

Alternative Surface Disinfection Explored in Latest Issue of American Journal of Infection Control (AJIC)

Groundbreaking research published in the February issue of the American Journal of Infection Control validates a new surface disinfection process that may one day replace chemical disinfectants in hospitals.

Seattle WA (Vocus) February 24, 2009 -- Groundbreaking research published in the February issue of the American Journal of Infection Control (http://www.ajicjournal.org/) validates a new surface disinfection process that may one day replace chemical disinfectants in hospitals. The process incorporates a saturated steam vapor system with TANCS® technology, harnessing the power of steam to eradicate antibiotic-resistant bacteria, viruses, and fungi on surfaces in less than 5 seconds.

The study, "Reduction in Infection Risk Through Treatment of Microbially Contaminated Surfaces With a Novel, Portable, Saturated Steam Vapor Disinfection System," (http://preview.tinyurl.com/ajicjournal) was designed and overseen by Dr. Benjamin Tanner, president and scientific director of Antimicrobial Test Laboratories (http://www.antimicrobialtestlaboratories.com/). The study set out to determine the capability of the TANCS-equipped steam vapor disinfection system to kill microorganisms, reduce surface-associated infection risks and serve as an alternative to chemical disinfectants.

"During rigorous testing, the TANCS system surprised us in several instances with its efficacy," Dr. Tanner said. "It has been gratifying to see the research peer-reviewed for AJIC and to have our lab findings published in a medium easily accessible to the infection control community."

Dr. Tanner and staff treated a diverse assortment of pathogenic organisms, including vancomycin-resistant Enterococcus faecalis (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and MS2 coliphage, with the TANCS system. Surface sanitation was observed within 2 seconds for most microorganisms, and all of the pathogens tested were completely inactivated within 5 seconds. Risks of infection from the contaminated surfaces clearly decreased with increasing periods of treatment.

The results confirm what Rick Hoverson, principal of Advanced Vapor Technologies (http://www.advap.com/tancs) (AVT), has seen in tests performed by other independent laboratories.

"The present level of HAIs, the ever-increasing number of multi-drug-resistant pathogens, along with concerns over use and exposure to chemicals, highlights the need for a simpler, safer, broader-spectrum and faster-acting surface disinfection protocol," Hoverson said. "This published paper represents a valid scientific basis for such a protocol."

TANCS, or Thermal Accelerated Nano Crystal Sanitation, is a patent-pending process available from AVT. According to the company, the TANCS chemical-free pre-treatment causes nano crystals to form in common tap water. When the TANCS-treated water is transformed into super-heated low-moisture steam, the crystals are energized and disrupt microbial cell walls and membranes. This, coupled with the protein denaturing effect of the moist heat, rapidly and reliably kills a broad range of pathogens.

"We are excited that this paper will create confidence and awareness in the infection prevention and environmental services sector that effective, less toxic alternatives are readily available," Hoverson said. "We believe that the more the infection control community learns about this efficacious alternative, the more the advantages will become apparent."

The American Journal of Infection Control (http://www.ajicjournal.org/) covers key topics and issues in infection control and epidemiology. Infection control professionals, including physicians, nurses, and epidemiologists, rely on AJIC for peer-reviewed articles covering clinical topics as well as original research. As the official publication of the Association for Professionals in Infection Control (APIC) and Epidemiology, Inc., AJIC is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention.

About Advanced Vapor Technologies

Seattle-based Advanced Vapor Technologies (AVT) provides state-of-the-art steam vapor sanitation systems that enable deep cleaning and disinfection, reducing the dependence on potentially harmful or corrosive chemicals. Carrying an EPA establishment number, TANCS steam vapor units have been tested and proven to disinfect surfaces in less time and with greater safety and efficacy than typical EPA-registered chemical disinfectants. For more information, contact Rick Hoverson, principal of Advanced Vapor Technologies (http://www.advap.com/tancs), at 800-997-6584.

About Antimicrobial Test Laboratories

Antimicrobial Test Laboratories (ATL) (http://www.antimicrobialtestlaboratories.com/) is an independent testing facility specializing in the research and development of antimicrobials, including disinfectants. ATL's principal Dr. Benjamin Tanner holds a B.S. in Molecular Biology and a Ph.D. in Microbiology and Immunology from the University of Arizona, where he studied environmentally mediated disease transmission and assessed infection risks for workers.

###

Contact Information Rick Hoverson

Advanced Vapor Technologies

http://www.advap.com/tancs

800-997-6584

VerteLoc™ Now Implanted in More than 230 Patients in US / VGI Announces New Interactive Website to Support Demand

VerteLoc™ Now Implanted in More than 230 Patients in US / VGI Announces New Interactive Website to Support Demand

VG Innovations, Inc (VGI), announced today that its revolutionary VerteLoc™ Minimally Invasive Spine Stabilization system has now been implanted in more than 230 patients across the United States. A new interactive website has now been launched to support the demand for the VerteLoc™ system.

Winston-Salem, NC (PRWEB) February 23, 2009 -- VG Innovations, Inc (VGI), (www.vginnovations.com) announced today that its revolutionary VerteLoc™ Minimally Invasive Spine Stabilization system has now been implanted in more than 230 patients across the United States.

VerteLoc™ is designed to address minor spinal instabilities by effectively stabilizing the spinal facets, which are multi-directional joints of the spinal column. By addressing these indications earlier in the continuum of spine care, it may serve to reduce or eliminate back pain caused by the facet joints.

"The interest from surgeons continues to grow on a weekly basis," stated VGI's President and CEO, Dan Grayson. "VerteLoc™ is making a significant difference in the way surgeons address minor instabilities caused by various spinal diseases. Our unique patent pending allograft implant design, which combines two unique geometric shapes, and innovative directional instrumentation allows our surgeon users to replicate the VerteLoc™ procedure in a variety of surgical approaches."

A new interactive website (www.verteloc.com) has now been launched to support the demand for the VerteLoc™ system. "With the assistance of Zero Gravity Design Associates (www.zgda.com) (ZGDA), we have created an informative and educational online tool that is unlike anything currently seen in this market space," Grayson added. "Jim Olsen, and his team at ZGDA, have assisted us to raise the bar with regard to the education and training of our current and potential surgeon users and distribution partners."

The VerteLoc™ Minimally Invasive Spine Stabilization System is designed to allow earlier intervention in the continuum of spinal care. The procedure should prolong or prevent more invasive spine procedures in indicated patients, which would provide significant benefits to the quality of life versus traditional methods of spinal fusion.

Company Profile

VG Innovations, Inc, (VGI) is a privately held company and was formed in late 2007. The company is in the business of developing and commercializing proprietary, implantable devices with a specific focus on minimally invasive surgical products that could provide better surgical solutions over present technology. The products are designed to treat specific spinal disease indications that affect millions of people. More information on the company and its products can be found at: www.verteloc.com

###

Contact Information Dan Grayson

VGI

http://www.verteloc.com

336-760-2012

Reprints Desk Named to "KMWorld 100 Companies that Matter in Knowledge Management" List

Reprints Desk Named to "KMWorld 100 Companies that Matter in Knowledge Management" List

Reprints Desk, Inc., the content workflow company, today announced that the company has been named as one of "KMWorld's 100 Companies that Matter in Knowledge Management" by KMWorld Magazine.

Los Angeles, Calif. (PRWEB) February 23, 2009 -- Reprints Desk, Inc., the content workflow company (http://www.reprintsdesk.com/main/home.aspx), today announced that the company has been named as one of "KMWorld's 100 Companies that Matter in Knowledge Management" by KMWorld Magazine.

KMWorld's annual list, now in its eighth year, is compiled by knowledge management (KM) practitioners, theorists, analysts, vendors, and customers. Companies that have previously been named to the list include Google, Apple, Oracle, SAP, and EMC.

"Each company embodies as part of its culture agile and limber execution of its mission, embracing a spirit of both adaptability and innovation," said Hugh McKellar, KMWorld editor in chief.

In 2008, Reprints Desk achieved a number of accomplishments:

• Ranked first overall and in each category within the Document Delivery (http://www.reprintsdesk.com/main/docdel_overview.aspx) Best Practices and Vendor Scorecard Report published by Outsell, Inc.

• Served more than 50% of the world's top-50 pharmaceutical companies

• Launched eCTD Article Service (http://www.reprintsdesk.com/main/news.aspx) for regulatory submissions

• Established an office in Germany to support European sales

• Became a document supplier on FIZ Karlsruhe's full-text broker service FIZ AutoDoc

• Signed an agreement with the Copyright Clearance Center to integrate rights management from Rightsphere into the document delivery workflow

Reprints Desk is headquartered in Los Angeles, California, and was founded in 2006 by document delivery pioneer Peter Derycz. The company provides software services that simplify how healthcare companies and other research-oriented enterprises procure, manage, and share peerreviewed journal articles and other copyright-protected content.

About KMWorld

The leading information provider serving the Knowledge, Document and Content Management systems market, KMWorld informs more than 50,000 subscribers about the components and processes - and subsequent success stories - that together offer solutions for improving business performance. KMWorld is a publishing unit of Information Today, Inc.

About Reprints Desk ®

Reprints Desk, Inc. (www.reprintsdesk.com), is a content technology and services company that simplifies how healthcare companies and other enterprises procure, manage and share scientific journal articles and other copyright-protected content. The company's workflow solutions and end user tools help customers effectively use peer-reviewed literature in product promotions, regulatory submissions, and research. A channel supplier for more than 100 scientific, technical, and medical (STM) publishers, Reprints Desk currently serves more than half of the world's Top-50 pharmaceutical companies and earned the #1 ranking in the 2008 Document Delivery Vendor Scorecard by Outsell, Inc. Reprints Desk is a Derycz Scientific, Inc. (OTC: DYSC.PK) company. For more information about Reprints Desk, contact Ian Palmer at +1 (707) 658-1931.

Public and Media Relations Contacts:

Ian Palmer, Head of Marketing

Reprints Desk, Inc. | +1 707.658.1931

ipalmer @ reprintsdesk.com

# # #

Contact Information Ian Palmer

Reprints Desk

http://www.reprintsdesk.com

707.658.1931

KettleWorx Launches "I Love My Kettlebell" National Media Tour

KettleWorx Launches "I Love My Kettlebell" National Media Tour

Fitness expert Ryan Shanahan to promote kettlebells as the ultimate fitness tool

Minneapolis, MN (PRWEB) February 23, 2009 -- KettleWorx announced its sponsorship of Ryan Shanahan's "I Love My Kettlebell" national media tour. Shanahan, creator of KettleWorx and the world's leading expert in kettlebell fitness, will be appearing on a series of television newscasts across the country to promote awareness of kettlebells as the ultimate fitness tool.

"It's the fastest and most effective fitness and weight loss tool available, but most people still don't know what a kettlebell is, or how to use it," said Shanahan. "Once people discover how easy it is to slim down and tone up with just three, 20 minute KettleWorx sessions a week, they really will 'love their kettlebell'."

"We're seeing more interest in kettlebells as a result of recent endorsements by athletes like Lance Armstrong and celebrities like Katherine Heigl and Penelope Cruz," said Steve Roberts, CEO of FitnessWorx, LLC. "But people need expert training if they are going to get the same benefits celebrities enjoy, which is why we partnered with Ryan in the creation of KettleWorx and now support his national media tour."

Ryan Shanahan appeared yesterday on the KTVK Phoenix program "Good Morning Arizona" and today on KNSD-TV in San Diego. He has previously appeared on the CBS Early Show, on the WTXF show "Good Day Philadelphia," and on KARE 11 in Minneapolis - St. Paul. Planned future appearances include "AM Northwest" on KATU in Portland and with KING 5 in Seattle.

About Ryan Shanahan

Ryan is the world's leading kettlebell expert and the developer of KettleWorx - the most comprehensive kettlebell training program available. Over the last 20 years he's played professional hockey, represented Canada at the World Duathlon Championship, completed 22 triathlons and 2 marathons. Having trained with nothing more than a 20 pound kettlebell, Ryan recently earned 2nd place at the Heavyweight Drug Free Bodybuilding Contest.

About KettleWorx

KettleWorx is the global leader in kettlebell fitness (http://kettleworx.com/) and offers a complete kettle bell workout (http://www.kettleworx.com/) program on DVD for home use. Designed to emulate a true personal trainer experience, KettleWorx is appropriate for men and women of any fitness level. Users are led through a series of gradually more challenging workouts that comprise the "Six Week Body Transformation."

For more information, visit www.KettleWorx.com

Contact:

Jimmy Clark, President

FitnessWorx, LLC

952-443-4185

jclark (at) KettleWorx.com

###

Contact Information Jimmy Clark

FitnessWorx, LLC

http://www.KettleWorx.com

952-443-4185

Separating Fact from Bioidentical Hype

Separating Fact from Bioidentical Hype

Hot from Menopausal Symptoms and Bothered by the Media Hype about Hormone Replacement? People are hearing about bioidentical hormone replacement along with more traditional types of prescribed hormone medication from the Oprah show and other media. Lets separate Fact from Fiction. The word "bioidentical" is not an accurate medical description of this new, unregulated substance and it certainly is not exactly like the hormones the body produces otherwise there would not be a measurable and clinically evident toxic build-up in the body. In "Revitalize Your Hormones: Dr. Dale's 7 Steps to a Happier, Healthier, and Sexier You" (Wiley; May 2005), Dr. Theresa Dale offers a medically proven natural alternative to invasive and dangerous hormone replacement therapies. Dale invented the world's only clinically proven, FDA registered, homeopathic hormone rejuvenation formulas used for restoring hormone balance without side effects.

(PRWEB) February 19, 2009 -- Hot from Menopausal Symptoms and Bothered by the Media Hype about Hormone Replacement? People are hearing about bioidentical hormone replacement along with more traditional types of prescribed hormone medication from the Oprah show and other media. Lets separate Fact from Fiction. The new buzz word "bioidentical" is deceptive. It's not an accurate medical description of this new, unregulated substance and it is not exactly like the body produces. Clearly there is a measurable and clinically evident toxic build-up in the body.

Bioidentical hormone replacement is not natural even though it originates from yam or soy; it has been compounded and thus a synthetic. That's right; health providers perform thousands of before and after saliva tests on patients and it is clear that there is a toxic build up of all hormone replacement including bioidentical HRT.

Women are wary of recent warnings linking hormone replacement therapy with an increased risk for heart disease, stroke and breast cancer, more and more women are turning to alternative and natural ways to balance their hormone levels. Studies have shown that using hormones such as Prempro, Othro-Prefest or Premphase and bioidentical HRT causes the body to shut down production of its own hormones creating a dependency. Hormone replacement therapy can also elevate existing hormone levels to toxically high amounts, which can tax the adrenal glands, burden the liver, kidneys, and circulatory and immune systems.

Yet, there is a superior way to get both clinically proven and evidence based relief without being exposed to the toxic effects of ALL of these drugs. Health providers throughout the US are using FDA registered NuFem & EndoPure Homeopathic Hormone Rejuvenation, developed by Theresa Dale, ND, CCN, NP.

In "Revitalize Your Hormones: Dr. Dale's 7 Steps to a Happier, Healthier, and Sexier You" (Wiley; May 2005; $15.95/Paper), Dr. Theresa Dale offers a medically proven alternative to invasive and dangerous hormone replacement therapies. With over 20 years of experience as a Naturopathic Doctor, Certified Clinical Nutritionist and researcher, Dr. Dale has helped women balance their hormone levels through safe, non-toxic program. The world's only clinically proven homeopathic hormone rejuvenation formulas used for restoring hormone balance without side effects. These formulas actually produce healthy hormone levels in women of various ages, and eliminate symptoms such as hot flashes, mood swings, low libido, low energy and irregular menses. The formulas are FDA approved and regulated and are prepared at an FDA registered pharmacy. The remedy goes through a lengthy preparation processes. For example, an herb or substance is diluted and prepared in a manner so that just a micro amount of the original substance is left in the final formula. This method of natural preparation enhances all the properties of the herb and amplifies its efficacy. Homeopathic medicine has been used for 200 years throughout the world, and is natural without toxic side effects. See The Wellness Center website for more education about Homeopathy.

The medical establishment's approach to balancing hormones fails to embrace the concept of the body as a natural living system that is capable of self-repair. Its regimens are based on the premise that people need to look outside our bodies for hormone help via one-size-fits-all drugs. The only hormones that are safe for the human body are the ones the body makes. By using a totally natural and homeopathic program, it is possible to restore emotional, physical and sexual health by following simple and safe individualized nutritional and exercise guidelines.

For more information, call Theresa Dale's office at 866 962 6484.

Theresa Dale, ND, CCN, NP

Founder, The Wellness Center For Research & Education, Inc.

Dean, California College of Natural Medicine

www.wellnesscenter.net

###

Contact Information Theresa Dale

The Wellness Center

http://www.wellnesscenter.net

866 962 6484

Dr. Theresa Dale, ND, CCN, NP

The Wellness Center

http://www.wellnesscenter.net

805 984 7200

Leading Ultraviolet (UV) Photonics Scientist to Consult for Optics Technology Company

Leading Ultraviolet (UV) Photonics Scientist to Consult for Optics Technology Company

Karl G. Linden, Ph.D., will provide expert oversight for Remote Light's custom design, validation and prototyping services for clean drinking water, safe air, and other sustainable environmental technology applications using UV optics.

Raleigh, N.C. -- Remote Light, Inc., an optics technology company, has engaged Professor Karl G. Linden as Chair of its UV Technology Committee. Dr. Linden is currently Professor of Environmental Engineering and Liebman Faculty Fellow at The University of Colorado at Boulder. He is an internationally known expert in applying UV technology for inactivation of microbial pathogens and UV-based oxidation for the degradation of environmental pollutants. Dr. Linden's research is funded by organizations such as the American Water Works Association Research Foundation, the WateReuse Foundation, US EPA, and the National Science Foundation. Dr. Linden is a founding Board Member and International Vice President of the International Ultraviolet Association.

"Based on an initial evaluation of the UV technology portfolio that integrates UV light, optics, and fiber optic technology, Remote Light is well positioned to introduce UV technology into a plethora of consumer and high technology products, providing significant public health benefits in the water, surface, and air disinfection areas," stated Dr. Linden. "I'm very excited to work with Remote Light and help their UV patent portfolio applications utilize new technologies like UV-LEDs. Remote's granted patents cover UV lighting for water and air applications enabling significant improvements to many consumer, commercial, and residential applications."

Isaac Horton, Ph.D., Chairman and CEO of Remote Light stated, "Now that we are moving forward with our UV optics technology licensing program, it is very strategic to our business model to have Dr. Linden join us."

About Remote Light, Inc.

Remote Light, Inc. has developed and patented a global portfolio of ultraviolet (UV) lighting technologies for drinking water, wastewater, other fluids, air, medical, consumer appliance and surface applications. Remote Light owns or controls more than 120 US and international granted patents, applications, and exclusive patent licenses combining optics with fiber optics and UV light for a broad range of purification and disinfection applications.

For more information about Remote Light, Inc. visit www.remotelight.com.

Contact:

Stephen Burnett

Sr. VP Technology Licensing

Remote Light, Inc.

1-910-274-4760 (m)

###

Contact Information Stephen Burnett

Remote Light, Inc.

http://www.remotelight.com

1-910-274-4760

Endoscopy Systems Market to Reach $4.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Endoscopy Systems Market to Reach $4.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

The market for endoscopy systems is projected to reach $4.5 billion by 2015. Growth in this dynamic market is driven by increasing acceptance of endoscopic techniques among physicians, extensive use of endoscopy procedures and technology advancements in areas such as robotics, miniaturization, and imaging.

San Jose, CA (PRWEB) February 19, 2009 -- Endoscopy systems occupy a significant position in the medical device market with applications extending over several areas in medical surgery. The market is driven by an aging population, demand for preventive screening procedures such as colorectal screening, and growing awareness among people towards this medical discipline. Endoscopic procedures are less risky, less painful, and involve lesser patient recovery period, when compared to traditional methods. Owing to escalating opportunities and demand for Minimally Invasive Endoscopy Surgery (MIES) procedures, several medical equipment manufacturers are focusing on developing products that are highly capable of offering minimally invasive surgeries.

US, Japan, and Europe comprise the largest markets, accounting for a major share of the global endoscopy systems market (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp), as stated in a recent report published by Global Industry Analysts, Inc. Asia-Pacific with increasing penetration of endoscopy procedures represents a potential market for endoscopy systems with CAGR of 5.8% for the next few years. An expanding chronically ill and aging population, improvements in endoscopy technologies and advancements in minimally invasive surgery technologies are driving the endoscopes (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp) market in the region. Globally, the market for Visualization equipment (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp) is largely driven by technological advancements such as high-definition camera systems, NBI, MBI technologies, and advancement in video processing, recording, and communication technologies.

Among the application areas, gastrointestinal endoscopy is rapidly trenching new opportunities with growing demand for initial cancer screening tests that facilitates survival prospects of the patient before the risk of metastasis. The segment is also driven by advancements such as capsule endoscopy, which is finding useful application in imaging the gastrointestinal tract including the small intestine. Growth in the market is expected to be further driven by release of novel products and expanding product indications.

The global marketplace is characterized by presence of players such as Boston Scientific Corporation, Conmed Corporation, Ethicon Endo-Surgery, Inc., Fujinon Corp., Given Imaging, Hoya Corporation, Karl Storz GmbH & Co. KG, Medtronic Neurologic Technologies, Olympus Corporation, Richard Wolf Medical Instruments Corporation, Smith & Nephew Plc, and Stryker Corporation.

"Endoscopy Systems: A Global Strategic Business Report", published by Global Industry Analysts, Inc. provides a comprehensive review of major market dynamics, trends, technology advancements, and competition pertaining to the market. The report enumerates recent product introductions/innovations, developments, mergers, acquisitions and other strategic industry activities. Product segments analyzed in the study include Endoscopes and Visualization Equipment. Analysis is presented for the periods 1995-2005 and 2006-2015 for established and emerging markets including the United States, Canada, Japan, France, Germany, United Kingdom, Italy, Spain, Asia-Pacific and Latin America.

For more details about this research report, please visit http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) (http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Web Site http://www.StrategyR.com

###

Contact Information Public Relations

Global Industry Analysts, Inc.

http://www.StrategyR.com/

(408) 528-9966

Green Bay Packers Install Digital Imaging System From Carestream Health At Lambeau Field

Green Bay Packers Install Digital Imaging System From Carestream Health At Lambeau Field

System Enables Rapid Medical Decisions on Game Day.

Rochester, NY (Vocus) February 18, 2009 -- Seconds count on the football field and they also count in the stadium's x-ray room. This need for speed is the reason Green Bay Packers personnel capture and view medical images of injured players using digital technology from Carestream Health, Inc. (www.carestreamhealth.com)

Each x-ray image is captured digitally in less than one minute. So in the time it used to take to process a single film image, athletic trainers and physicians can complete an entire imaging exam and view it on a workstation to determine the severity of an injury, how to treat it and whether the player can return to the game.

"Having immediate access to a digital image is a huge advantage when we need to make decisions about whether a player can return to the game," said Pepper Burruss, Head Athletic Trainer, Green Bay Packers. "This system also delivers excellent image quality, which is not only critical for game-day decisions, but also for making medical decisions during practices and training camp."

The recently installed imaging solution consists of a KODAK DIRECTVIEW Classic CR System for digital image capture, a workstation for image viewing and short-term storage, a laser printer and a CD burner. Visiting teams also benefit from this digital imaging solution, since medical exams on their players can be burned to CDs for convenient storage and access. In the future, the Packers also plan to electronically transmit imaging studies to orthopedic specialists and physicians in remote locations.

"We believe our digital imaging solution delivers significant advantages for professional sports teams. Being able to digitally capture and store high-quality digital x-ray images can help protect the health of each player and can ultimately enhance the team's performance," said Connie Pettijohn, Vice President of Corporate Accounts and Strategic Alliances, Carestream Health (www.carestreamhealth.com). "Implementing our digital imaging solution is a smart business decision for the team and an excellent benefit for the players."

About Carestream Health, Inc. (www.carestreamhealth.com):

Carestream Health, Inc., is a leading provider of dental and medical imaging systems and healthcare IT solutions; molecular imaging systems for the life science research and drug discovery/development market segments; and x-ray film and digital x-ray products for the non-destructive testing market. Headquartered in Rochester, N.Y., and serving customers in more than 150 countries, Carestream Health is an independent company operating within the family of companies owned by Onex Corporation (TSX: OCX.TO) of Toronto, Canada. For more information about Carestream Health, contact your Carestream Health representative or visit www.carestreamhealth.com/.

CARESTREAM and DIRECTVIEW are trademarks of Carestream Health, Inc.

KODAK is a trademark of Kodak used under license.

Media Contacts:

Robert Salmon

585-627-6560

robert.salmon (at) carestreamhealth.com

Robette Brooks

303-699-8861

rbrooks60 (at) earthlink.net

###

Contact Information Robert Salmon

Carestream Health, Inc.

http://www.carestreamhealth.com

585-627-6560